Cognitive Enhancement in Depression (The COG-D Study)
Non-invasive Neuromodulation to Enhance Targeted Cognitive Remediation in Older Adults With Depression
This study will investigate whether transcranial direct current stimulation (tDCS) enhances the effects of computerized cognitive training in older adults with recurrent depression (2 or more lifetime episodes; either current or within past 3 years).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The purpose of this study is to determine whether the addition of active tDCS to computerized cognitive remediation (nCCR) enhances brain activity and cognitive functions in older adults with recurrent depression to a greater degree than nCCR with sham stimulation. The investigators will randomize 20 elderly depressed outpatients to either double-blinded active or sham bifrontal tDCS plus daily nCCR over 4-weeks. Multimodal MRI (focused on the cognitive control network; CCN) and psychiatric and neuropsychological evaluations will be obtained at baseline and following intervention completion. Long-term CCN cognitive effects will be explored 3-months post-intervention via cognitive assessments.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 60+ years
- Diagnosis of a current or past (within last 3 years) depressive episode (e.g., Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD)) using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
- In total, participants must have 2 or more lifetime depressive episodes to be considered "recurrent"
- Either stable antidepressant regimen for at least 6 weeks or no current antidepressant treatment
- Evidence of subjective cognitive complaints on the Everyday Cognition Scale (ECog)
- English fluency
Exclusion criteria:
- Other Axis I psychiatric conditions via the DSM-5, except for anxiety symptoms occurring in a depressive episode
- Acute suicidality on clinical evaluation
- Acute grief
- History of alcohol use disorder or substance use disorder in last 12 months
- Currently taking medications that would significantly interact with tDCS effects (such as sodium channel blockers or anticonvulsants)
- Neurological disorders (e.g., dementia, stroke, seizures, traumatic brain injury, Parkinson's disease)
- Montreal Cognitive Assessment (MoCA) score < 23
- Primary amnestic cognitive profile (>1.5 standard deviations (SDs) below demographically-adjusted mean on National Alzheimer's Coordinating Center (NACC) memory measures in context of otherwise normal cognitive profile)
- Any physical or intellectual disability affecting ability to complete assessments
- Unstable medical illness needing urgent treatment
- MRI contraindications
- Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last 2 months
- Current involvement in psychotherapy
- Current involvement in other research studies (including but not limited to: neuromodulation [TMS or tDCS] or investigational drug studies)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cognitive Training + Active Stimulation
This arm receives cognitive training combined with active tDCS. |
Computerized cognitive training targeting the underlying cerebral networks associated with depression. A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system). |
|
Experimental: Cognitive Training + Sham Stimulation
This arm receives cognitive training combined with sham tDCS. |
Computerized cognitive training targeting the underlying cerebral networks associated with depression. Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Task-based fMRI Activation Within the Cognitive Control Network During the N-back Task
Time Frame: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
MRI scans were performed at baseline (T1) and after completion of the intervention (4 to 6 weeks later; T2). MRI measured Cognitive Control Network function, operationalized as change in n-back functional MRI response in the anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), and the posterior parietal cortex (PPC) regions of interest. The n-back functional MRI response was calculated as the activation difference (beta values) between 2-back and 0-back conditions of the n-back. Higher scores indicate more activation during the 2-back condition compared to the 0-back condition. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
N-back Behavioral Performance (Accuracy)
Time Frame: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Target accuracy data on the n-back were extracted for each n-back condition (2-back and 0-back). Higher scores for the metrics indicated better accuracy. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
N-back Behavioral Performance (Response Time)
Time Frame: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Target response time data on the n-back were extracted for each n-back condition (2-back and 0-back). Lower scores indicate faster response times. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
NIH Examiner Scores
Time Frame: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Computerized neuropsychological battery to assess range of executive functions. The Executive Composite represents overall executive function performance across multiple neuropsychological measures. Item Response Theory (IRT) Empirical Bayes scoring based on the saved parameters from the 3 factors (Working Memory, Cognitive Control, Fluency) are used to generate scores, which are not a norm-referenced measure and are not adjusted for age. The composite is presented in the original metric used in the IRT algorithm. Scores range from -1.50 to 1.52. Higher scores mean better executive function. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
California Verbal Learning Test, 2nd Edition (CVLT-2) Scores
Time Frame: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
The California Verbal Learning Test, 2nd edition (CVLT-2) is a standardized measure of verbal learning and memory. Raw scores are obtained and converted to age and sex-adjusted z-scores, with 0 indicating population average. Positive values indicate of better than average learning and memory performances. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Montgomery Asberg Depression Rating Scale (MADRS) Scores)
Time Frame: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Depression rating scale that ranges from 0-60, with higher scores indicating greater depressive symptom severity. For percent change, post-intervention (T2) was compared to baseline (T1), with higher negative values indicating greater decrease in depressive symptoms at T2 compared to baseline. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sarah M. Szymkowicz, PhD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Behavioral Symptoms
- Pathological Conditions, Signs and Symptoms
- Behavior
- Signs and Symptoms
- Depression
- Neurobehavioral Manifestations
- Therapeutics
- Patient Care
- Health Services
- Health Care Facilities Workforce and Services
- Behavioral Disciplines and Activities
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Electric Stimulation Therapy
- Convulsive Therapy
- Psychiatric Somatic Therapies
- Electroshock
- Psychological Techniques
- Neurological Rehabilitation
- Transcranial Direct Current Stimulation
- Cognitive Training
Other Study ID Numbers
Other Study ID Numbers
- 220283
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.